Inactive Instrument

GRI Bio, Inc.

Equities

GRI

US3622AW2059

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-05-14 EDT			5-day change	1st Jan Change
0.4007 ^USD	-1.18%		+2.72%	-85.13%

05-21	GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus	CI
05-20	GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis	CI

GRI Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 04:08 pm

GRI Bio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 13.04 million compared to USD 3.22 million a year ago. Basic loss per share from continuing operations was USD 28.25 compared to USD 24.95 a year ago.

Latest news about GRI Bio, Inc.

GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus	05-21	CI
GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis	05-20	CI
GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators with Issuance of Korea Patent	04-16	CI
GRI Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
GRI Bio, Inc. Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	03-04	CI
GRI Bio's Board Approves 1-for-7 Reverse Stock Split to Regain Nasdaq Compliance	01-26	MT
GRI Bio, Inc. Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis	12-05	CI
GRI Bio Secures FDA Clearance for Investigational New Drug Application for Pulmonary Fibrosis Treatment	11-27	MT
GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis	11-27	CI
GRI Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Top Premarket Gainers	23-09-15	MT
GRI Bio to Sell ADAIR Assets, Intellectual Property to Aardvark Therapeutics	23-08-23	MT
Top Premarket Gainers	23-07-03	MT
GRI Bio, Inc. Appoints Leanne Kelly as Chief Financial Officer	23-04-25	CI
GRI Bio, Inc. completed the acquisition of Vallon Pharmaceuticals, Inc. from group of shareholders in a reverse merger transaction.	23-04-20	CI
GRI Bio, Inc. announced that it has received $2.5 million in funding from Altium Capital Management LP	23-04-19	CI
GRI Bio, Inc. Auditor Raises 'Going Concern' Doubt	23-02-23	CI
GRI Bio, Inc. Auditor Raises 'Going Concern' Doubt	22-12-22	CI
GRI Bio, Inc. entered into a definitive agreement to acquire Vallon Pharmaceuticals, Inc. from group of shareholders for $49 million in a reverse merger transaction.	22-12-12	CI

Chart GRI Bio, Inc.

Duration

Period

More charts

Company Profile

GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).

Sector

More about the company